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Abstract Within the past ten years, small incision pars-
plana vitrectomy, and refined microsurgical techniques,
together with the introduction of various intravitreally
applied drugs, significantly improved the anatomical and
functional outcome. Unfortunately many diabetic patients
with vitreoretinal complications also have cataract. In
diabetic retinopathy, the benefit of simultaneous cataract
surgery was long under debate due to possible side effects
such as fibrinous reaction or secondary glaucoma. We
review recent reports about the results of PPV for
complication of diabetic retinopathy and the influence of a
simultaneous cataract surgery, that compare different
surgical approaches. Pars plana vitrectomy carried out with
conventional 0,9 mm incisions (20G PPV) were related to
higher incidences of postoperative inflammatory reactions
and to a higher frequency of postoperative hypertensive
events as compared to small incision vitrectomy (23G
PPV). Postoperative recovery was faster in eyes with 23G
surgery than after 20G surgery, with no delay by a
simultaneous cataract surgery. A 23G-PPV improves the
postoperative recovery and the quality of life for the
diabetic patient. Cataract is no longer an obstacle for a
vitreoretinal surgery. Postoperative recovery is faster and
the new technique has less side effects than the conven-
tional technique. In the future, a drug assisted vitrectomy
will further reduce the surgical trauma. However, the new
options are not equally benefitial for all patients. A further
improvement in the quality of life will require a more
individualized approach of microsurgical treatment for
ocular complications of diabetes.
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Introduction
Diabetes care and eye diseases: status quo
Diabetes mellitus is an increasing problem in healthcare
with a high socioeconomic impact. Around 8 million
diabetics live in Germany, not all of whom are aware of
their disease [1]. Around 1.5 million are visually impaired
due to diabetic retinopathy. Diabetic retinopathy is the
leading cause for blindness in the age below 65 in the
industrialized world.
Ocular manifestations of diabetes mellitus are exudative
or proliferative vitreoretinopathy [2], vitreous hemorrhage,
tractional retinal detachments, cataract and secondary
glaucoma.
New developments in instrumentation allow very subtle
vitreoretinal microsurgery, followed by a minimal postop-
erative inflammatory reaction, but require excellent con-
ditions for illumination and observation. Therefore, not
rarely the surgeon has to decide whether to combine a
vitreoretinal surgery with a cataract surgery [3].
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The problem of coexisting cataract and retinal disease
in diabetic patients
A cataract may already preoperatively appear in such an
advanced stage, that a pars plana vitrectomy is not possible,
before cataract surgery has been performed. However, also
a less advanced cataract may initially allow a pars plana
vitrectomy. But due to osmotic alterations during surgery it
may advance within minutes during the vitrectomy proce-
dure and impair the visibility of the retinal structures, so
that the subtle surgery cannot be completed without
simultaneous cataract surgery. Already a limited pars plana
vitrectomy with macular surgery is regularly followed by a
significant cataract within months [4], so that the issue of a
prophylactic cataract surgery has to be addressed.
If a significant cataract is already present at the time, the
pars plana vitectomy is indicated, it has to be decided,
whether to perform a cataract surgery prior to the vitrectomy
or simultaneously. In some institutions, cataract surgeries
and vitrectomies are performed by different surgeons, while
in other institutions both procedures are performed by the
same surgeon. This paper will not discuss the logistic issue
of a complex surgery performed by two surgeons, but will
focus on the results that can be achieved by modern surgery.
However, the aforementioned ocular manifestations of
diabetes (such as exudative or proliferative vitreoretinop-
athy [2], vitreous hemorrhage, tractional retinal detach-
ments, cataract and secondary glaucoma) have in common
an impaired blood retinal barrier. Any intraocular surgical
procedure additionally affects this barrier. As a conse-
quence, surgery for a complication of diabetic retinopathy
is followed by an increased postoperative inflammatory
reaction as compared to other indications.
Combination of pars plana with simultaneous cataract
surgery versus a two separate procedures
After cataract surgery in a diabetic patient, the potential
visual recovery may be limited by a postoperative fibrinous
membrane or by an early after-cataract formation [5]. This
complication was even more frequently observed following
cataract surgery with an implantation of a Polymethylme-
thacrylate (PMMA) intraocular lens as compared to a
modern acryl lens. Therefore, 25 years ago, a simultaneous
cataract surgery was avoided if possible, and an implanta-
tion of an intraocular lens in an eye with active proliferative
retinopathy was regarded as contraindicated. In younger
patients, moderate lens opacities have been found to
progress following vitrectomy only in 5% of the cases [6].
However, most of the diabetic patients scheduled for
vitrectomy nowadays are older and will develop cataract
in a significantly higher percentage.
25 years ago, vitreoretinal surgery in an eye with an
advanced proliferative diabetic retinopathy including iris
neovascularization and advanced cataract as well as the
necessity to perform a lensectomy during vitrectomy was
associated with an unfavorable outcome and thus should be
avoided [7]. Not rarely, a cataract surgery with intraocular
lens implantation was followed by a deterioration of the
diabetic retinopathy during the postoperative healing
process resulting in a neovascular glaucoma before vitrec-
tomy could be performed. Following extracapsular cataract
extraction with intraocular lens (IOL) implantation, a
rubeosis iridis and neovascularization within the lens
capsule supporting the IOL developped, a condition termed
rubeosis capsularis [8]. On the other hand a vitrectomy with
preservation of the lens in an eye with advanced diabetic
retinopathy and rubeosis iridis was followed by a fibrinoid
reaction, continued inflammation and resulted in phthisis in
13%, because the peripheral retina could not be adequately
treated and peripheral vitreoretinal membranes could only
insufficiently be dissected [9]. The occurrence of silicone
oil-induced cataract following vitreoretinal silicone oil
surgery is an unavoidable complication due the metabolic
changes. Following extracapsular cataract extraction, ex-
treme fibrosis und shrinkage of the posterior lens capsule
was observed.
To overcome the dilemma of progressing proliferations and
massive fibrinous reactions following cataract surgery in an
eye that also urgently needed vitreoretinal surgery, it was
advised to perform an intracapsular cataract extraction without
an IOL during vitreoretinal surgery and IOL-implantation at
the earliest 3 months after all retinal interventions have been
completed and the retina is stable [10].
After the introduction of small incision surgeries and
ameliorated lens materials the frequency of the aforemen-
tioned complications could be reduced. In addition, a
shorter surgical time helped to reduce the postoperative
inflammatory effect. In addition, nowadays most of the
diabetic patients receive panretinal photocoagulation prior
to vitreoretinal surgery so that the proliferations are less
fulminant even in advanced situations than they were
25 years ago. 10 years ago it was found that cataract
extraction and simultaneous IOL implantation during
vitreous surgery for proliferative diabetic retinopathy may
improve the visual outcome in more than 90% of selected
eyes without significant complications [11].
On the other hand a cataract surgery in previously
vitrectomized eyes is still difficult and associated with a
higher complication rate. In a prospective study of 100
consecutive eyes of patients who developed a cataract after
PPV, intraoperative complications including posterior cap-
sular tears (4%), luxated nucleus into vitreous (2%), and
zonular dialysis (5%) and postoperative complications
including vitreous hemorrhage (6%), retinal redetachment
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(4%), pupillary synechiae (6%), ocular hypertension (4%), and
fistulation (3%) were found more frequently than in non-
vitrectomized eyes. The visual results were limited by retinal
comorbidity as well as by the surgical complications [12].
Nowadays, it is widely believed, that a cataract surgery
performed together with a vitreoretinal surgery, does not
increase the time needed for the vitreoretinal part of the
surgery and does not increase the complication rate [13].
We could confirm these findings [14, 15]. Furthermore, the
combination of both procedures eliminates the need for
further surgery, ameliorates the visibility within the
vitreoretinal procedure and enhances the postoperative
visual recovery [16]. The time needed for hospitalization
is shorter after a combined surgery as compared to separate
surgeries [14, 15]. Even more, the postoperative develop-
ment of iris and angle neovascularization could be
completely prevented by combining vitrectomy with pha-
coemulsification, while it was 15% in the vitrectomy alone
group [17].
When pars plana vitrectomy is combined with cataract
surgery, the extent of the postoperative inflammatory
reaction and the postoperative complications may depend
on the following factors:
1. surgical approach of cataract surgery
2. composition of the intraocular lens material
3. surgical approach to vitrectomy
4. duration of surgery
We will further discuss to what extent these factors may
determine the postoperative inflammatory reaction and how
further complications of diabetes in the eye may be
prevented.
Surgical approach of cataract surgery
As already mentioned above, the results of a combined
extracapsular cataract surgery (ECCE), that required an
11 mm corneoscleral incision, a posterior chamber intraoc-
ular lens implantation (PC/IOL) and a 20G pars plana
vitrectomy were limited by a fibrinous reaction and a
potentially progressing neovascularization in patients with
advanced diabetic retinopathy. In less advanced stages of
retinopathy, the combined ECCE/PC-IOL implantation and
pars plana vitrectomy was a well-tolerated surgical proce-
dure for diabetics, which can provide clear anterior and
posterior segment media already 20 years ago, with a
doubling of visual acuity in the average [18].
When vitrectomy was combined with cataract removal
by phacoemulsification instead of extracapsular extraction,
the complication rate was further reduced. Suzuki et al.
reviewed postoperative complications after simultaneous
vitrectomy, phacoemulsification, aspiration, and acryl lens
insertion. Combined surgery was performed in 155 eyes
with diabetic retinopathy between 1995 and 1997. Postop-
erative observation was continued in all of them for more
than 6 months. In patients with diabetic retinopathy,
reoperations were needed for intravitreal hemorrhage in
21 eyes (13.5%), rubeotic glaucoma in 6 eyes (3.9%), other
diseases in 4 eyes (2.6%), and a removal of an intraocular
lens was needed in 10 eyes (6.5%). [19]. Yet, a fibrinous
exudation was found in 30% of the eyes [20].
After having changed from phacoemulsification via a
sclerocorneal tunnel incision to a clear cornea incision we
could show that the rate of a fibrinous exsudation was
reduced from 38% to 26% [21]. Thus we could confirm
Diolaiuti et al, who found a rate of a limited postoperative
fibrin formation in 22% of eyes [22].
A bimanual technique for phacoemulsification may
allow an even better stabilization of the anterior chamber
during vitreoretinal surgery without serious postoperative
complications. This technique improves the quality of
combined surgery, ensures stability of the anterior chamber,
reduces postoperative astigmatism and lowers the risk of
inflammation [23].
Composition of the intraocular lens material
Implantation of a PMMA-IOL more often causes a
postoperative fibrinous reaction than a foldable acrylic
IOL [21, 23]. The inflammatory reaction of a foldable
acrylic IOL is comparable to that of a heparin coated
PMMA IOL. Foldable acrylic IOLs allow small incisions
ranging between 3.2 and 1.8 mm with a minimized
postoperative astigmatism, and a minimized risk of inflam-
mation [23].
Surgical approach to vitrectomy
While 23-gauge pars plana vitrectomy demonstrated short-
term visual outcomes and complication rates comparable to
those reported with 20- and 25-gauge systems [24], we
could show a reduced postoperative inflammatory reaction
following 23G PPV as compared to 20G PPV, not only for
PPV alone, but also for procedures combined with cataract
surgery with a clear cornea approach [25]. In the postop-
erative antiinflammatory treatment we used dexamethasone
eye drops either 6 times or 12 times a day. If the reaction
was very pronounced, we injected 4 mg of dexamethasone
subconjunctivally. For the analysis, this would equal 24
drops (24 DE or drop equivalents) of dexamethasone. Other
drugs, that modulate the postoperative inflammatory reac-
tion, were not used. The approach to PPV affected the
postoperative inflammatory reaction as well as the approach
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to cataract surgery: a 20G PPV combined with a 6 mm
wide sclerocorneal tunnel caused a higher degree of ocular
injury and therefore a higher postoperative inflammatory
response with a fibrine reaction in 38% of cases and a
steroid use of 17.2 drop equivalents (DE). The injury
caused by a 20G PPV combined with a 3 mm clear cornea
tunnel incision is smaller, resulting in less frequent fibrine
reactions (26%) and a reduced steroid consumption (12.4
DE). The 23G PPV approach combined with a 3 mm clear
cornea tunnel for cataract surgery produces the least trauma,
with rare fibrine reactions (3%) and only 8.6 DE of local
steroids. Thus we were able to confirm findings by
Valmaggia [26], who also found a reduced inflammatory
reaction not only following 25G PPV as compared to 20G
PPV alone, but also following with cataract surgery
combined procedures. However, the time needed for the
final visual recovery does not differ between small and
standard incision vitrectomy (25G as compared to 20G)
[27].
Future developments: drug assisted vitrectomy
The use of triamcinolone acetonide stains the vitreous and
reduces a postoperative inflammatory reaction. Birinci dem-
onstrated that a combined clear corneal phacoemulsification
with foldable intraocular lens implantation (IOL) and triam-
cinolone assisted pars plana vitrectomy in patients with
proliferative diabetic retinopathy simplified the surgery and
decreased the postoperative inflammation [28]. As compared
to our results, the rate of a fibrinous iritis was further reduced
from 26% to 11% [21, 28]. However, the use of intravitreal
triamcinolone is associated with a 30% risk of a postoper-
ative ocular hypertension or secondary glaucoma [29],
However, intravitreal triamcinolone should not be applied
subsequent to vitrectomy and peeling of the membrana
limitans interna [30], as it could be shown that triamcinolone
crystals demonstrate pronounced cytotoxicity if allowed to
directly adhering to denuded ganglion cells [31].
Mechanical vitrectomy is incomplete. Remnants of the
cortical vitreous may cause vitreoretinal traction and (re)
proliferation of cells. A pharmacologic vitreolysis with
microplasmin facilitates a complete posterior vitreous
detachment without mechanical manipulation at the vitre-
oretinal interface and is a less traumatic approach than
vitrectomy [32, 33]. It might be of a special benefit in
retinal diseases characterized by fibrocellular and fibrovas-
cular proliferations, such as diabetic macular edema and
proliferative retinopathy, in order to prevent advanced
stages of disease [33]. In a completely vitrecomized eye
the oxygen supply to the retina is improved, resulting in a
lower expression of vasoactive substances such as vascular
endothelial growth factor [33, 34].
An intravitreal injection of bevacizumab significantly
decreased the free VEGF in the aqueous humor by 7 days,
an intraoperative hemorrhage was less likely to occur [35].
An intravitreal injection of bevacizumab injection before
vitrectomy for PDR facilitates the surgery, reduces the time
needed for surgery by 30%, and may improve the visual
acuity results of the operation [36]. It was shown in a
randomized study that it also decreases the rate of
postoperative vitreous hemorrhage [37].
Duration of surgery
Over the last 25 years the time needed for PPV was largely
reduced from about 90 min to 30 min. However, the
reduced inflammation is not primarily related to a reduced
surgical time. We previously investigated the cut-closure-
time for 20G and 23G PPV and found out that is did not
differ significantly (18,5±5,9 min vs 19,8±6,4 min for 20G
vs 23G-PPV), while the inflammatory reaction was further
reduced following 23G PPV as compared to 20G PPV [25].
The reduction of time needed for the preparation and
closure of the sclerotomies in 23G and 25G vitrectomies is
compensated by the longer time needed for the vitrectomy
itself with the smaller instruments [27, 38]. Therefore, we
conclude from our data, that the observed effect of a
reduced inflammatory reaction following 23G PPV as
compared to 20G PPV is induced by minimizing the
surgical trauma itself.
Combination of vitrectomy with cataract suregry versus
two sequential surgeries improves individual outcomes
Combining vitrectomy with phacoemulsification and posterior
capsulectomy allows patients who often have bilateral vitreor-
etinal disease to come to a stable postoperative vision in the
eye requiring vitreous surgery much earlier than three separate
procedures spread out over months or years [39]. Combined
surgery may prevent a second operation for postvitrectomy
cataract, allowing earlier visual rehabilitation [40].
Minimizing the surgical trauma will further improve
the individual outcome
Minimizing the surgical trauma for the cataract part of the
surgery as well as for the vitrectomy part results in a
reduced postoperative inflammatory reaction [25]. In
addition a reduced surgical time further reduces the
postoperative inflammatory reaction. However the recent
change from standard 20G PPV to 23G PPV did not reduce
the overall needed time between cut and suture [25]. The
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reduction of time needed for the preparation and closure of
the sclerotomies in 23G and 25G vitrectomies is compen-
sated by the longer time needed for the vitrectomy itself
with the smaller instruments [27, 38]. The use of
triamcinolone acetonide may even further simplify surgery
and decrease the postoperative inflammation [28].
We have shown that a combination of small incision
vitrectomy with a small incision cataract surgery via a clear
cornea approach did not increase the postoperative inflam-
matory reaction and the amount of antiinflammatory drugs
needed postoperatively when compared to vitrectom alone
[21]. In a combined procedure, neither the time needed for
vitreoretinal surgery is prolonged nor the complication rate
increased [13]. Rather, the intraoperative visualization of
the vitreoretinal structures is ameliorated and the postoper-
ative visual recovery is quicker [16]. Finally, the economic
burden of a combined procedure is lower than for two
separate procedures [41].
Predictive indicators that determine the best
individualized treatment
A high degree of neovascularization, especially in the
anterior part of the eye, was a prognostic indicator for an
unfavorable outcome. With the recent advent of intravitreally
applied drugs that block the neovascular effect of the
vasoproliferative growth factor (VEGF), this problem can
be overcome now. A patient with a coexisting cataract,
proliferative retinal disease and iris neovascularization or
even with a neovascular glaucome should be pretreated with
an intravitreally applied anti-VEGF substance, such as
bevacizumab or ranibizumab about 3–7 days prior to the
combined surgery [36, 37]. An intravitreal injection of
bevacizumab significantly decreased the free VEGF in the
aqueous humor by 7 days, an intraoperative hemorrhage was
less likely to occur [35]. An intravitreal injection of
bevacizumab injection before vitrectomy for PDR facilitates
the surgery, reduces the time needed for surgery by 30%,
and may improve the visual acuity results of the operation
[36]. It was shown in a randomized study that it also
decreases the rate of postoperative vitreous hemorrhage [37].
Conclusion
The developments in modern small incision techniques in
ocular microsurgery helped to reduce the postoperative
inflammatory reaction and thus improved the postoperative
recovery and the quality of life for the diabetic patient. Due
to the reduced surgical trauma, the diabetic patient may
now receive a complete treatment without risking the side
effects of this treatment. An impending cataract is no longer
an obstacle for a vitreoretinal surgery as both problems can
be addressed simultaneously without risking an impaired
functional outcome. Postoperative recovery is faster and the
new technique has less side effects than the conventional
technique. Thus, following minimally-invasive diagnostics,
the new micro-incisional techniques allow an optimal
therapy planning and a personalized patient treatment,
combined with a substantial improvement of the quality
of life when compared to previous techniques. The addition
of drugs, such as steroids or anti-VEGF drugs or micro-
plasmin, may facilitate and fasten the surgery and further
minimize the surgical trauma. In addition, the new surgical
techniques allow a more complete surgery, and the
combination of techniques that previously had to be
separated into distinct surgical procedures, result in a
reduction of the economic burden of diabetes complications
in the eye. However, the classic therapeutic options like
laser coagulation still have their place in the portfolio of
treatment strategies. The enlarged portfolio of treatment
options requires an individualized approach, as not all
options are equally benefitial for all diabetic patients. Thus,
a further evaluation in prospective studies is necessary to
reach the goal of an evidence based, predictive and
personalized medicine.
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